SE9701398D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9701398D0
SE9701398D0 SE9701398A SE9701398A SE9701398D0 SE 9701398 D0 SE9701398 D0 SE 9701398D0 SE 9701398 A SE9701398 A SE 9701398A SE 9701398 A SE9701398 A SE 9701398A SE 9701398 D0 SE9701398 D0 SE 9701398D0
Authority
SE
Sweden
Prior art keywords
pct
date
novel compounds
sec
pub
Prior art date
Application number
SE9701398A
Other languages
English (en)
Swedish (sv)
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9701398A priority Critical patent/SE9701398D0/xx
Publication of SE9701398D0 publication Critical patent/SE9701398D0/xx
Priority to SK1356-99A priority patent/SK135699A3/sk
Priority to EP98917859A priority patent/EP0975636B1/en
Priority to IL13215398A priority patent/IL132153A0/xx
Priority to IDW991207A priority patent/ID22746A/id
Priority to JP54380398A priority patent/JP2001520645A/ja
Priority to PL98336230A priority patent/PL336230A1/xx
Priority to CA002286078A priority patent/CA2286078A1/en
Priority to AU70909/98A priority patent/AU733066B2/en
Priority to AT98917859T priority patent/ATE245648T1/de
Priority to EEP199900465A priority patent/EE9900465A/xx
Priority to TR1999/02538T priority patent/TR199902538T2/xx
Priority to KR1019997009435A priority patent/KR20010006350A/ko
Priority to HU0002104A priority patent/HUP0002104A3/hu
Priority to CN98806075A priority patent/CN1259951A/zh
Priority to DE69816608T priority patent/DE69816608T2/de
Priority to PCT/SE1998/000640 priority patent/WO1998046606A1/en
Priority to BR9808540-9A priority patent/BR9808540A/pt
Priority to US09/068,304 priority patent/US6028074A/en
Priority to IS5198A priority patent/IS5198A/is
Priority to NO995006A priority patent/NO995006L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
SE9701398A 1997-04-15 1997-04-15 Novel compounds SE9701398D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
BR9808540-9A BR9808540A (pt) 1997-04-15 1998-04-07 Composto, processo para a preparação do mesmo, composição farmacêutica e processo para preparação dos mesmos, uso de um composto, e, processo para produzir a imunossupressão
AU70909/98A AU733066B2 (en) 1997-04-15 1998-04-07 Novel compounds
EEP199900465A EE9900465A (et) 1997-04-15 1998-04-07 Uued ühendid
IL13215398A IL132153A0 (en) 1997-04-15 1998-04-07 Novel compounds
IDW991207A ID22746A (id) 1997-04-15 1998-04-07 Senyawa-senyawa baru
JP54380398A JP2001520645A (ja) 1997-04-15 1998-04-07 新規な化合物
PL98336230A PL336230A1 (en) 1997-04-15 1998-04-07 Novel chemical compounds
CA002286078A CA2286078A1 (en) 1997-04-15 1998-04-07 Novel compounds
SK1356-99A SK135699A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione compounds, preparation method thereof, pharmaceutical composition containing them and their use
AT98917859T ATE245648T1 (de) 1997-04-15 1998-04-07 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
EP98917859A EP0975636B1 (en) 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-diones as t-cell proliferation inhibitors
TR1999/02538T TR199902538T2 (xx) 1997-04-15 1998-04-07 Yeni bile�imler.
KR1019997009435A KR20010006350A (ko) 1997-04-15 1998-04-07 신규 화합물
HU0002104A HUP0002104A3 (en) 1997-04-15 1998-04-07 Pyrazolo[3,4-d]pyrimidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
CN98806075A CN1259951A (zh) 1997-04-15 1998-04-07 新化合物
DE69816608T DE69816608T2 (de) 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
PCT/SE1998/000640 WO1998046606A1 (en) 1997-04-15 1998-04-07 Novel compounds
US09/068,304 US6028074A (en) 1997-04-15 1998-08-07 Pyrazolo[3,4-d]pyrimidineone compounds
IS5198A IS5198A (is) 1997-04-15 1999-09-27 Ný efnasambönd
NO995006A NO995006L (no) 1997-04-15 1999-10-14 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Publications (1)

Publication Number Publication Date
SE9701398D0 true SE9701398D0 (sv) 1997-04-15

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds

Country Status (21)

Country Link
US (1) US6028074A (hu)
EP (1) EP0975636B1 (hu)
JP (1) JP2001520645A (hu)
KR (1) KR20010006350A (hu)
CN (1) CN1259951A (hu)
AT (1) ATE245648T1 (hu)
AU (1) AU733066B2 (hu)
BR (1) BR9808540A (hu)
CA (1) CA2286078A1 (hu)
DE (1) DE69816608T2 (hu)
EE (1) EE9900465A (hu)
HU (1) HUP0002104A3 (hu)
ID (1) ID22746A (hu)
IL (1) IL132153A0 (hu)
IS (1) IS5198A (hu)
NO (1) NO995006L (hu)
PL (1) PL336230A1 (hu)
SE (1) SE9701398D0 (hu)
SK (1) SK135699A3 (hu)
TR (1) TR199902538T2 (hu)
WO (1) WO1998046606A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004527541A (ja) 2001-03-01 2004-09-09 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US9226885B2 (en) * 2005-05-24 2016-01-05 Allium Vitalis Incorporated Personal care and medicinal products incorporating bound organosulfur groups
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
EP2023729B1 (en) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
MX2010006208A (es) * 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
KR20110095881A (ko) 2008-12-06 2011-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US8664207B2 (en) 2008-12-06 2014-03-04 Intra-Cellular Therapies, Inc. Organic compounds
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
EA201170772A1 (ru) * 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
ES2580759T3 (es) 2008-12-06 2016-08-26 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US8633180B2 (en) 2008-12-06 2014-01-21 Intra-Cellular Therapies, Inc. Organic compounds
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
PE20120774A1 (es) * 2009-03-23 2012-06-27 Glenmark Pharmaceuticals Sa COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
SG184766A1 (en) 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
JP2012521406A (ja) 2009-03-23 2012-09-13 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としてのフロピリミジンジオン誘導体
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2782898T3 (es) 2009-05-29 2020-09-16 Novartis Ag Métodos de administración de compuestos agonistas de la trombopoyetina
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
SG11201408093PA (en) 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
RU2679142C2 (ru) 2013-03-15 2019-02-06 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2014145617A2 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Novel uses
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
TWI686394B (zh) 2014-08-07 2020-03-01 美商內胞醫療公司 有機化合物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
RU2709786C2 (ru) 2014-12-06 2019-12-20 Интра-Селлулар Терапиз, Инк. Органические соединения
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP6964099B2 (ja) * 2016-06-23 2021-11-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン誘導体
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077372A1 (de) * 1981-04-22 1983-04-27 Byk Gulden Lomberg Chemische Fabrik GmbH NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (en) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
KR0170567B1 (ko) * 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
KR20010006350A (ko) 2001-01-26
HUP0002104A3 (en) 2002-03-28
BR9808540A (pt) 2000-05-23
CA2286078A1 (en) 1998-10-22
EP0975636A1 (en) 2000-02-02
SK135699A3 (en) 2000-05-16
NO995006D0 (no) 1999-10-14
WO1998046606A1 (en) 1998-10-22
JP2001520645A (ja) 2001-10-30
NO995006L (no) 1999-10-14
IL132153A0 (en) 2001-03-19
TR199902538T2 (xx) 2000-02-21
EP0975636B1 (en) 2003-07-23
IS5198A (is) 1999-09-27
ATE245648T1 (de) 2003-08-15
PL336230A1 (en) 2000-06-19
AU733066B2 (en) 2001-05-03
CN1259951A (zh) 2000-07-12
EE9900465A (et) 2000-04-17
HUP0002104A2 (hu) 2001-01-29
ID22746A (id) 1999-12-09
US6028074A (en) 2000-02-22
DE69816608D1 (de) 2003-08-28
AU7090998A (en) 1998-11-11
DE69816608T2 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
SE9701398D0 (sv) Novel compounds
EE200000318A (et) Uudsed ühendid
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
SE9702001D0 (sv) Novel compounds
HUT75776A (en) Pyrazolo and pyrrolopyridines, their using, pharmaceutical compositions containing them and intermediates
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HUP0104318A2 (hu) cGMP PDE-5 inhibitort tartalmazó szabályzottan hatóanyagot felszabadító gyógyászati készítmények
SE9702772D0 (sv) Novel compounds
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
SE9904129D0 (sv) Novel compounds
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
AU7436098A (en) Use of mizolastine for preparing a medicine for treating inflammation